Bio-Technology General regulatory update

The FDA accepted for filing BTGC's PMA for BioLon, its viscoelastic 1 percent solution of sodium hyaluronate, for use in ophthalmic surgical procedures such as cataract removal. BioLon is sold in 17 c...